Literature DB >> 11000007

Design and solution structure of functional peptide mimetics of nerve growth factor.

N Beglova1, S Maliartchouk, I Ekiel, M C Zaccaro, H U Saragovi, K Gehring.   

Abstract

The C-D loop in nerve growth factor (NGF) is involved in binding to the NGF receptor, TrkA. It is flexible and adopts several different types conformations in different NGF crystal forms. We have previously shown that a small cyclic peptide derived from the C-D loop of NGF binds to the TrkA receptor by mimicking the structure of this loop. To understand structure-function relationships in NGF C-D loop mimetics, we have produced a series of peptides predicted to form different types of beta-turns. The peptides were tested for their ability to promote cell survival in serum-free medium and to induce TrkA tyrosine phosphorylation. NMR structural studies were used to determined the backbone conformation and the spatial orientation of side chains involved in binding to the TrkA receptor. Peptides that form type I or type gammaL-alphaR beta-turns were the most active. The variety of active loop conformations suggests that the mimetics (and NGF) accommodate the binding site on TrkA by an 'induced fit' mechanism. In agreement with this hypothesis, NMR relaxation measurements detected both fast and slow motion in the peptides. We also characterized a retro-inverso peptide derived from the NGF C-D loop. This D-amino acid cyclic peptide did not adopt a conformation homologous to the NGF C-D loop and was inactive. This may be representative of difficulties in producing structural and functional mimetics by retro-inverso schemes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11000007     DOI: 10.1021/jm990441x

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  Role of the conformational versatility of the neurotrophin N-terminal regions in their recognition by Trk receptors.

Authors:  Francesca Stanzione; Luciana Esposito; Antonella Paladino; Carlo Pedone; Giancarlo Morelli; Luigi Vitagliano
Journal:  Biophys J       Date:  2010-10-06       Impact factor: 4.033

2.  Novel low-molecular-weight mimetics of the nerve growth factor.

Authors:  T A Gudasheva; T A Antipova; S B Seredenin
Journal:  Dokl Biochem Biophys       Date:  2010-10-20       Impact factor: 0.788

3.  Molecular simulation of the binding of nerve growth factor peptide mimics to the receptor tyrosine kinase A.

Authors:  Marco Berrera; Antonino Cattaneo; Paolo Carloni
Journal:  Biophys J       Date:  2006-06-23       Impact factor: 4.033

4.  A peptidomimetic of NT-3 acts as a TrkC antagonist.

Authors:  Fouad Brahimi; Andrey Malakhov; Hong Boon Lee; Mookda Pattarawarapan; Lubijca Ivanisevic; Kevin Burgess; H Uri Saragovi
Journal:  Peptides       Date:  2009-07-30       Impact factor: 3.750

5.  Bivalent peptidomimetic ligands of TrkC are biased agonists and selectively induce neuritogenesis or potentiate neurotrophin-3 trophic signals.

Authors:  Dianjun Chen; Fouad Brahimi; Yu Angell; Yu-Chin Li; Jennifer Moscowicz; H Uri Saragovi; Kevin Burgess
Journal:  ACS Chem Biol       Date:  2009-09-18       Impact factor: 5.100

6.  Amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity.

Authors:  Sung-Wuk Jang; Xia Liu; Chi-Bun Chan; David Weinshenker; Randy A Hall; Ge Xiao; Keqiang Ye
Journal:  Chem Biol       Date:  2009-06-26

7.  Low molecular weight, non-peptidic agonists of TrkA receptor with NGF-mimetic activity.

Authors:  D Scarpi; D Cirelli; C Matrone; G Castronovo; P Rosini; E G Occhiato; F Romano; L Bartali; A M Clemente; G Bottegoni; A Cavalli; G De Chiara; P Bonini; P Calissano; A T Palamara; E Garaci; M G Torcia; A Guarna; F Cozzolino
Journal:  Cell Death Dis       Date:  2012-07-05       Impact factor: 8.469

8.  Combinatorial assembly of small molecules into bivalent antagonists of TrkC or TrkA receptors.

Authors:  Fouad Brahimi; Eunhwa Ko; Andrey Malakhov; Kevin Burgess; H Uri Saragovi
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

9.  Nerve growth factor inhibitor with novel-binding domain demonstrates nanomolar efficacy in both cell-based and cell-free assay systems.

Authors:  Allison E Kennedy; Corey A Laamanen; Mitchell S Ross; Rahul Vohra; Douglas R Boreham; John A Scott; Gregory M Ross
Journal:  Pharmacol Res Perspect       Date:  2017-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.